Literature DB >> 16982784

Role of Asp104 in the SHV beta-lactamase.

Christopher R Bethel1, Andrea M Hujer, Kristine M Hujer, Jodi M Thomson, Mark W Ruszczycky, Vernon E Anderson, Marianne Pusztai-Carey, Magdalena Taracila, Marion S Helfand, Robert A Bonomo.   

Abstract

Among the TEM-type extended-spectrum beta-lactamases (ESBLs), an amino acid change at Ambler position 104 (Glu to Lys) results in increased resistance to ceftazidime and cefotaxime when found with other substitutions (e.g., Gly238Ser and Arg164Ser). To examine the role of Asp104 in SHV beta-lactamases, site saturation mutagenesis was performed. Our goal was to investigate the properties of amino acid residues at this position that affect resistance to penicillins and oxyimino-cephalosporins. Unexpectedly, 58% of amino acid variants at position 104 in SHV expressed in Escherichia coli DH10B resulted in beta-lactamases with lowered resistance to ampicillin. In contrast, increased resistance to cefotaxime was demonstrated only for the Asp104Arg and Asp104Lys beta-lactamases. When all 19 substitutions were introduced into the SHV-2 (Gly238Ser) ESBL, the most significant increases in cefotaxime and ceftazidime resistance were noted for both the doubly substituted Asp104Lys Gly238Ser and the doubly substituted Asp104Arg Gly238Ser beta-lactamases. Correspondingly, the overall catalytic efficiency (kcat/Km) of hydrolysis for cefotaxime was increased from 0.60 +/- 0.07 microM(-1) s(-1) (mean +/- standard deviation) for Gly238Ser to 1.70 +/- 0.01 microM(-1) s(-1) for the Asp104Lys and Gly238Ser beta-lactamase (threefold increase). We also showed that (i) k3 was the rate-limiting step for the hydrolysis of cefotaxime by Asp104Lys, (ii) the Km for cefotaxime of the doubly substituted Asp104Lys Gly238Ser variant approached that of the Gly238Ser beta-lactamase as pH increased, and (iii) Lys at position 104 functions in an energetically additive manner with the Gly238Ser substitution to enhance catalysis of cephalothin. Based on this analysis, we propose that the amino acid at Ambler position 104 in SHV-1 beta-lactamase plays a major role in substrate binding and recognition of oxyimino-cephalosporins and influences the interactions of Tyr105 with penicillins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982784      PMCID: PMC1694000          DOI: 10.1128/AAC.00848-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs.

Authors:  Xiaojun Wang; George Minasov; Brian K Shoichet
Journal:  J Mol Biol       Date:  2002-06-28       Impact factor: 5.469

2.  High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae.

Authors:  L B Rice; L L Carias; A M Hujer; M Bonafede; R Hutton; C Hoyen; R A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

3.  Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme.

Authors:  Michiyoshi Nukaga; Kayoko Mayama; Andrea M Hujer; Robert A Bonomo; James R Knox
Journal:  J Mol Biol       Date:  2003-04-18       Impact factor: 5.469

Review 4.  A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Authors:  K Bush; G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

5.  A new TEM beta-lactamase double mutant with broadened specificity reveals substrate-dependent functional interactions.

Authors:  H Viadiu; J Osuna; A L Fink; X Soberón
Journal:  J Biol Chem       Date:  1995-01-13       Impact factor: 5.157

6.  Amino acid substitutions at Ambler position Gly238 in the SHV-1 beta-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins.

Authors:  Andrea M Hujer; Kristine M Hujer; Marion S Helfand; Vernon E Anderson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

7.  Acyl-intermediate structures of the extended-spectrum class A beta-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin.

Authors:  Tatsuro Shimamura; Akiko Ibuka; Shinya Fushinobu; Takayoshi Wakagi; Masaji Ishiguro; Yoshikazu Ishii; Hiroshi Matsuzawa
Journal:  J Biol Chem       Date:  2002-09-08       Impact factor: 5.157

8.  Structural bases of stability-function tradeoffs in enzymes.

Authors:  Beth M Beadle; Brian K Shoichet
Journal:  J Mol Biol       Date:  2002-08-09       Impact factor: 5.469

9.  International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial Infections.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Ann Intern Med       Date:  2004-01-06       Impact factor: 25.391

10.  Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.

Authors:  Marion S Helfand; Monica A Totir; Marianne P Carey; Andrea M Hujer; Robert A Bonomo; Paul R Carey
Journal:  Biochemistry       Date:  2003-11-25       Impact factor: 3.162

View more
  18 in total

1.  Use of novel boronic acid transition state inhibitors to probe substrate affinity in SHV-type extended-spectrum beta-lactamases.

Authors:  Jodi M Thomson; Fabio Prati; Christopher R Bethel; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

2.  Novel insights into the mode of inhibition of class A SHV-1 beta-lactamases revealed by boronic acid transition state inhibitors.

Authors:  Wei Ke; Jared M Sampson; Claudia Ori; Fabio Prati; Sarah M Drawz; Christopher R Bethel; Robert A Bonomo; Focco van den Akker
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

3.  Role of SHV β-lactamase variants in resistance of clinical Klebsiella pneumoniae strains to β-lactams in an Algerian hospital.

Authors:  Nadjia Ramdani-Bouguessa; Vera Manageiro; Daniela Jones-Dias; Eugénia Ferreira; Mohamed Tazir; Manuela Caniça
Journal:  J Med Microbiol       Date:  2011-03-17       Impact factor: 2.472

4.  High tolerance to simultaneous active-site mutations in TEM-1 beta-lactamase: Distinct mutational paths provide more generalized beta-lactam recognition.

Authors:  Pierre-Yves De Wals; Nicolas Doucet; Joelle N Pelletier
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

5.  Effect of nosocomial bloodstream infections on mortality, length of stay, and hospital costs in older adults.

Authors:  Keith S Kaye; Dror Marchaim; Ting-Yi Chen; Timothy Baures; Deverick J Anderson; Yong Choi; Richard Sloane; Kenneth E Schmader
Journal:  J Am Geriatr Soc       Date:  2014-01-17       Impact factor: 5.562

6.  Strategic design of an effective beta-lactamase inhibitor: LN-1-255, a 6-alkylidene-2'-substituted penicillin sulfone.

Authors:  Priyaranjan Pattanaik; Christopher R Bethel; Andrea M Hujer; Kristine M Hujer; Anne M Distler; Magdalena Taracila; Vernon E Anderson; Thomas R Fritsche; Ronald N Jones; Sundar Ram Reddy Pagadala; Focco van den Akker; John D Buynak; Robert A Bonomo
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

7.  Substitutions at position 105 in SHV family β-lactamases decrease catalytic efficiency and cause inhibitor resistance.

Authors:  Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton; Marion J Skalweit
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

8.  Enhancing resistance to cephalosporins in class C beta-lactamases: impact of Gly214Glu in CMY-2.

Authors:  Andrea Endimiani; Yohei Doi; Christopher R Bethel; Magdalena Taracila; Jennifer M Adams-Haduch; Alexandra O'Keefe; Andrea M Hujer; David L Paterson; Marion J Skalweit; Malcolm G P Page; Sarah M Drawz; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-02-09       Impact factor: 3.162

9.  The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.

Authors:  Sarah M Drawz; Christopher R Bethel; Kristine M Hujer; Kelly N Hurless; Anne M Distler; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2009-06-02       Impact factor: 3.162

10.  Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1.

Authors:  Michiyosi Nukaga; Christopher R Bethel; Jodi M Thomson; Andrea M Hujer; Anne Distler; Vernon E Anderson; James R Knox; Robert A Bonomo
Journal:  J Am Chem Soc       Date:  2008-08-30       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.